Directory

Jacob Corn

Professor of Genome Biology | PhD | Berkeley, USA

The Corn Lab develops and uses next-generation genome editing and regulation technologies. They work on both fundamental biological discovery and potential therapies for human genetic diseases. Our focus is the mechanisms by which cells repair their DNA, maintain and differentiate hematopoietic stem cells, and use ubiquitin signaling to propagate cellular signals. Through technology development, mechanistic cellular biochemistry, and translational projects, they are working to unravel complex cellular phenotypes to further biological understanding and improve human health.

Jacob is committed to the improvement of human health through the fundamental understanding of disease mechanisms. Over the last fifteen years he has bridged academia and industry, working in therapeutic areas that include infectious disease, neurobiology, and oncology. His graduate studies at the University of California, Berkeley redefined our understanding of DNA replication and his postdoctoral work at the University of Washington computationally designed protein inhibitors from scratch. Prior to joining the Innovative Genomics Institute, Jacob was a group leader at Genentech where he discovered biological mechanisms for challenging therapeutic targets. In his spare time, Jacob enjoys long backpacking trips and rock climbing.

The Latest

News & Events

Dominika Michalíková Receives the 2026 Winn/Byrd Award for Adults With FA

The Fanconi Cancer Foundation is pleased to recognize Dominika as the first-place recipient of the 2026 Winn/Byrd Award for Adults with FA. Dexter Sherrell received the second-place award for his work connecting people affected by rare diseases with researchers, health care professionals and advocates.

Read More >

FCF and American Cancer Society Open 2026 Discovery Boost Grant for FA Cancer Research

We’re thrilled to announce a new partnership between the Fanconi Cancer Foundation (FCF) and the American Cancer Society (ACS): the Fanconi Cancer Foundation Discovery Boost Grant. This grant program will fuel innovative research aimed at preventing, detecting, and treating cancers associated with Fanconi anemia (FA).

Read More >

Building the Evidence for Safer Cancer Care in FA

FCF has committed $631,164 to three projects addressing critical gaps in FA cancer research. The work spans different stages, from exploring oral gene therapy and screening drugs for FA-specific safety to analyzing clinical experiences that could inform future care. These projects are building the knowledge needed to pursue safer cancer options for people with FA.

Read More >